Volume 26, Number 4—April 2020
Research
Genomic Insight into the Spread of Meropenem-Resistant Streptococcus pneumoniae Spain23F-ST81, Taiwan
Yi-Yin Chen1, Yu-Chia Hsieh1
, Yu-Nong Gong, Wei-Chao Liao, Shiao-Wen Li, Ian Yi-Feng Chang, Tzu-Lung Lin, Ching-Tai Huang, Cheng-Hsiu Chiu, Tsu-Lan Wu, Lin-Hui Su, Ting-Hsuan Li, and Ya-Yu Huang
, Yu-Nong Gong, Wei-Chao Liao, Shiao-Wen Li, Ian Yi-Feng Chang, Tzu-Lung Lin, Ching-Tai Huang, Cheng-Hsiu Chiu, Tsu-Lan Wu, Lin-Hui Su, Ting-Hsuan Li, and Ya-Yu Huang
Table 1
Serotype distribution and penicillin and meropenem susceptibility rates of invasive Streptococcus pneumoniae isolates from 2 tertiary hospitals in Taiwan, 2013−2017*†
| Serotype | Isolates, no. | No. (%) isolates |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meropenem |
Penicillin, meningitis |
Penicillin, nonmeningitis |
||||||||||
| S | I | R | S | I | R | S | I | R | ||||
| PCV7 | ||||||||||||
| 4 | 4 | 3 (75) | 1 (25) | 0 | 3 (75) | NC | 1 (25) | 4 (100) | 0 | 0 | ||
| 6B | 8 | 6 (75) | 2 (25) | 0 | 1 (12.5) | NC | 7 (87.5) | 8 (100) | 0 | 0 | ||
| 9V | 2 | 2 (100) | 0 (0) | 0 | 2 (100) | NC | 0 | 2 (100) | 0 | 0 | ||
| 14 | 18 | 4 (22.2) | 14 (77.8) | 0 | 1 (5.6) | NC | 17 (94.4) | 18 (100) | 0 | 0 | ||
| 18C | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| 19F | 18 | 3 (16.7) | 8 (44.4) | 7 (38.9) | 1 (5.6) | NC | 17 (94.4) | 14 (77.8) | 4 (22.2) | 0 | ||
| 23F | 10 | 5 (50) | 5 (50) | 0 | 0 | NC | 10 (100) | 10 (100) | 0 | 0 | ||
| Subtotal |
60 |
23 (38.3) |
30 (50) |
7 (11.7) |
8 (13.3) |
NC |
52 (86.7) |
56 (93.3) |
4 (6.7) |
0 |
||
| PCV13−non-PCV7 | ||||||||||||
| 1 | 1 | 0 | 1 (100) | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
| 3 | 15 | 15 (100) | 0 | 0 | 9 (60) | NC | 6 (40) | 15 (100) | 0 | 0 | ||
| 5 | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| 6A | 7 | 3 (42.9) | 4 (57.1) | 0 | 1 (14.3) | NC | 6 (85.7) | 7 (100) | 0 | 0 | ||
| 7F | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| 19A | 36 | 4 (11.1) | 13 (36.1) | 19 (52.8) | 0 | NC | 36 (100) | 31 (86.1) | 5 (13.9) | 0 | ||
| Subtotal |
59 |
22 (37.3) |
18 (30.5) |
19 (32.2) |
10 (16.9) |
NC |
49 (83.1) |
54 (91.5) |
5 (8.5) |
0 |
||
| PPV23−non-PCV13 | ||||||||||||
| 8 | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| 10A | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| 11A | 4 | 2 (50) | 1 (25) | 1 (25) | 2 (50) | NC | 2 (50) | 4 (100) | 0 | 0 | ||
| 15B | 17 | 1 (5.9) | 8 (47.1) | 8 (47.1) | 0 | NC | 17 (100) | 16 (94.1) | 1 (5.9) | 0 | ||
| 20 | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| 22F | 3 | 3 (100) | 0 | 0 | 3 (100) | NC | 0 | 3 (100) | 0 | 0 | ||
| 33F | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
| Subtotal |
24 |
6 (25) |
9 (37.5) |
9 (34.6) |
5 (19.2) |
NC |
19 (79.2) |
23 (95.8) |
1 (3.9) |
0 |
||
| NVT | ||||||||||||
| 6C | 1 | 1 (100) | 0 | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
| 7B/C | 2 | 2 (100) | 0 | 0 | 1 (50) | NC | 1 (50) | 2 (100) | 0 | 0 | ||
| 9A/L | 2 | 2 (100) | 0 | 0 | 1 (50) | NC | 1 (50) | 2 (100) | 0 | 0 | ||
| 11B | 1 | 1 (100) | 0 | 0 | 1 (100) | NC | 0 | 1 (100) | 0 | 0 | ||
| 11C | 1 | 1 (100) | 0 | 0 | 1 (100) | NC | 0 | 1 (100) | 0 | 0 | ||
| 12 | 2 | 0 | 2 (100) | 0 | 0 | NC | 2 (100) | 2 (100) | 0 | 0 | ||
| 15A | 20 | 7 (35) | 12 (60) | 1 (5) | 2 (10) | NC | 18 (90) | 19 (95) | 1 (5) | 0 | ||
| 15C | 12 | 2 (16.7) | 8 (66.7) | 2 (16.7) | 2 (16.7) | NC | 10 (83.3) | 10 (100) | 0 | 0 | ||
| 15F | 1 | 0 | 1(100) | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
| 18F | 1 | 0 | 1 (100) | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
| 19B | 1 | 1 (100) | 0 | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
| 23A | 14 | 10 (71.4) | 3 (21.4) | 1 (7.2) | 0 | NC | 14 (100) | 14 (100) | 0 | 0 | ||
| 23B | 2 | 1 (50) | 1 (50) | 0 | 0 | NC | 2 (100) | 2 (100) | 0 | 0 | ||
| 35A/C | 2 | 1 (50) | 1 (50) | 0 | 1 (50) | NC | 1 (50) | 2 (100) | 0 | 0 | ||
| 35B | 1 | 1 (100) | 0 | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
| Subtotal | 63 | 30 (47.6) | 29 (46) | 4 (6.3) | 9 (14.3) | NC | 54 (85.7) | 58 (98.3) | 1 (1.7) | 0 | ||
*I, intermediate; NC, not calculated; NVT, nonvaccine type; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; R, resistant; S, susceptible.
†MICs for meropenem: S, <0.25; I, 0.5; R, >1; for penicillin, meningitis: S, <0.06; R, >0.12; and for penicillin, nonmeningitis: S, <2; I, 4; R, >8.
1These first authors contributed equally to this article.
Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.